• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Outset Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/30/24 4:05:11 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $OM alert in real time by email
    8-K
    0001484612false00014846122024-05-292024-05-29

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 29, 2024

    Outset Medical, Inc.

    (Exact name of Registrant as Specified in Its Charter)

    Delaware

    001-39513

    20-0514392

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

     

     

    3052 Orchard Dr.,

    San Jose, California

    95134

    (Address of Principal Executive Offices)

    (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (669) 231-8200

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

     

    OM

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    On May 29, 2024, Outset Medical, Inc. (the “Company”) held its Annual Meeting of Stockholders at 1:30 p.m. Pacific Time in a virtual format via live audio webcast (the “Annual Meeting”). As of April 2, 2024, the Company’s record date, there were a total of 51,702,159 shares of common stock outstanding and entitled to vote at the Annual Meeting. At the beginning of the Annual Meeting, 38,482,261 shares of common stock were present virtually in person or by proxy, and, therefore, a quorum was present. Three items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below.

    Proposal One: Election of Class I Directors

    Each of Karen Drexler, Dale E. Jones and Leslie Trigg was elected to serve as a class I director to hold office until the Company’s 2027 annual meeting of stockholders and until the election and qualification of his or her successor. Votes were cast as follows:

    For

    Withheld

    Broker Non-Votes

    Karen Drexler

    25,813,322

    7,579,904

    5,089,035

    Dale E. Jones

    32,551,383

    841,843

    5,089,035

    Leslie Trigg

    32,066,397

    1,326,829

    5,089,035

     

     

     

     

     

     

     

    Since the Board is divided into three classes with one class elected each year to hold office for a three-year term, the following directors continued to serve as directors of the Company immediately after the Annual Meeting: D. Keith Grossman, Patrick T. Hackett, Jim Hinrichs, Brent D. Lang and Andrea L. Saia.

    Proposal Two: Advisory Vote on Named Executive Officer Compensation

    The proposal to approve the 2023 compensation of the Company’s named executive officers as disclosed in its 2024 proxy statement on a non-binding advisory basis was approved by the following vote:

    For

    Against

    Abstain

    Broker Non-Votes

    16,832,317

    16,462,009

    98,900

    5,089,035

    Proposal Three: Ratification of Appointment of Independent Registered Public Accounting Firm

    The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following vote:

    For

    Against

    Abstain

    Broker Non-Votes

    38,253,001

     128,630

    100,630

    —

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Outset Medical, Inc.

     

    Date: May 30, 2024

    By:

    /s/ John Brottem

    John Brottem

    General Counsel

     

     


    Get the next $OM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OM

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    6/21/2024$5.00 → $6.00Sector Perform → Outperform
    RBC Capital Mkts
    4/8/2024$6.00Buy
    BTIG Research
    4/5/2024$6.00Neutral → Buy
    CL King
    1/12/2024$14.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    10/13/2023$32.00 → $3.00Buy → Underperform
    BofA Securities
    8/17/2023Neutral
    CL King
    11/11/2022$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $OM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Elliott Derick A.

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    4/8/26 5:21:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Elliott Derick A.

    3 - Outset Medical, Inc. (0001484612) (Issuer)

    4/8/26 5:19:32 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: New insider Leonard Braden Michael claimed ownership of 1,902,201 shares (SEC Form 3)

    3/A - Outset Medical, Inc. (0001484612) (Issuer)

    3/4/26 11:17:19 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SAN JOSE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity (the "Company"), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company's Inducement Plan, as a material inducement to employment to Derick Elliott, the Company's newly appointed Executive Vice President of Commercial, as well as one newly appointed non-executive employee, in each case, who were not previous employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Li

    4/8/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Names Derick Elliott as Executive Vice President of Commercial

    SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced the appointment of Derick Elliott as Executive Vice President of Commercial, effective immediately. Mr. Elliott is responsible for Outset's commercial organizations supporting acute, post-acute and home healthcare providers, reporting to Chair and CEO Leslie Trigg. He joins Outset with more than 30 years of sales and marketing experience from Stryker, Cardinal Health and most recently SpendMend, a private company where he successfully drove a comm

    4/6/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned

    SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) of its next-generation Tablo platform, designed to deliver enterprise-level security, reliability and connectivity for hospitals, health systems and home providers of dialysis. With the clearance, Tablo becomes the first hemodialysis system incorporating FDA's most rigorous and recent guidance on medical device cybersecurity published in June 2025. Additionally, enhancements to the har

    1/27/26 9:00:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.

    SCHEDULE 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    3/27/26 11:19:26 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 144 filed by Outset Medical Inc.

    144 - Outset Medical, Inc. (0001484612) (Subject)

    2/17/26 9:16:07 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.

    SCHEDULE 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    2/17/26 4:14:59 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Leadership Updates

    Live Leadership Updates

    View All

    Outset Medical Names Derick Elliott as Executive Vice President of Commercial

    SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced the appointment of Derick Elliott as Executive Vice President of Commercial, effective immediately. Mr. Elliott is responsible for Outset's commercial organizations supporting acute, post-acute and home healthcare providers, reporting to Chair and CEO Leslie Trigg. He joins Outset with more than 30 years of sales and marketing experience from Stryker, Cardinal Health and most recently SpendMend, a private company where he successfully drove a comm

    4/6/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

    SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, and named Karen N. Prange to its board of directors. Unaudited Fourth Quarter and 2025 Results Revenue in the fourth quarter totaled approximately $28.9 million, bringing revenue for 2025 to approximately $119.5 million, a 5% increase over $113.7 million in 2024.Exiting 2025, more than 1,000 sites of care have insourced dialysis with Outset, performing roughly 1 million treatments per year and more t

    1/12/26 8:30:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

    SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

    5/14/25 9:00:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Financials

    Live finance-specific insights

    View All

    Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. E

    1/26/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025

    SAN JOSE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter 2025 after the close of trading on Monday, November 10, 2025. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Mo

    10/27/25 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2025. Second Quarter and Recent Highlights Net revenue of $31.4 million grew 15% from the prior-year period, driven by a 25% increase in Tablo console revenue.Recurring revenue consisting of Tablo consumables and services grew 11% over the prior-year period to $22.5 million, driven by a 17% increase in consumable revenue.Gross margin was 37.8%, or 38.4% on a non-GAAP basis, a 110 basis-point improvement over the prior

    8/6/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:53:46 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:26:01 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 10:32:13 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Outset Medical downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $3.00 from $6.00 previously

    8/8/24 6:47:35 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Outset Medical from Sector Perform to Outperform and set a new price target of $6.00 from $5.00 previously

    6/21/24 6:53:06 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on Outset Medical with a new price target

    BTIG Research initiated coverage of Outset Medical with a rating of Buy and set a new price target of $6.00

    4/8/24 7:26:20 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care